| Literature DB >> 26248332 |
Chun-Fu Yeh1, Tsui-Ping Liu2, Chun-Wen Cheng3, Shih-Cheng Chang4, Ming-Hsun Lee3, Jang-Jih Lu4.
Abstract
OBJECTIVES: Staphylococcus lugdunensis can cause community- and healthcare-associated infections. This study investigated the molecular characteristics of S. lugdunensis isolates collected at our hospital and compared the characteristics of the infectious and commensal isolates.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26248332 PMCID: PMC4527845 DOI: 10.1371/journal.pone.0134859
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primers used in polymerase chain reaction amplification and sequencing of the agr locus in this study.
| Primer | 5′-3′ Sequence | Gene | Purpose | Size of amplicon (bp) |
|---|---|---|---|---|
| SL_agr-F/SL_agr-R | ATAATGATACCAAGGAGCGTG/ CGAACCTTTAGCTTATCTGTACC |
| screening | 1626 |
| SL_agr-1-F/SL_agr-R | CTGTCATCCTTAGTGTAATTGCTG/ CGAACCTTTAGCTTATCTGTACC |
|
| 586 |
| SL_agr-2-F/SL_agr-R | GCCGGCATAATAGTCCCTTCTG/CGAACCTTTAGCTTATCTGTACC |
|
| 771 |
Fig 1Multiplex PCR for agr gene typing of Staphylococcus lugdunensis.
(Lanes M: marker; 19: S. lugdunensis No. 19; 20: S. lugdunensis No. 20; 21: S. lugdunensis No. 21; 22: S. lugdunensis No. 22).
118 Staphylococcus lugdunensis isolates obtained from various samples.
| Sample | Number | Percentage (%) |
|---|---|---|
| Blood | 105 | 89.0 |
| Ascites | 6 | 5.1 |
| Body fluid | 2 | 1.7 |
| Synovial fluid | 2 | 1.7 |
| Amniotic fluid | 1 | 0.8 |
| Cerebrospinal fluid | 1 | 0.8 |
| Pleural effusion | 1 | 0.8 |
Distribution of infection group and commensal group of 118 Staphylococcus lugdunensis isolates.
| Number | Percentage (%) | |
|---|---|---|
|
| 67 | 56.8 |
| Primary bacteremia | 29 | 24.6 |
| Catheter-related | 10 | 8.5 |
| Arteriovenous graft/fistula | 6 | 5.1 |
| Bone and joints | 6 | 5.1 |
| Infective endocarditis | 4 | 3.4 |
| Intra-abdomen | 4 | 3.4 |
| Skin and soft tissue | 3 | 2.5 |
| CAPD peritonitis | 2 | 1.7 |
| Central nervous system | 1 | 0.8 |
| Genital system | 1 | 0.8 |
| Lung | 1 | 0.8 |
|
| 51 | 43.2 |
Antibiotic resistance, distribution of SCCmec types and agr types, and δ-hemolytic activity among infectious and commensal Staphylococcus lugdunensis isolates.
| Total, n = 118, Number (%) | Infection, n = 67, Number (%) | Commensal, n = 51, Number (%) |
| |
|---|---|---|---|---|
|
| ||||
| Penicillin-R | 90 (76.3) | 48 (71.6) | 42 (82.4) | 0.1773 |
| Oxacillin-R | 43 (36.4) | 21 (31.3) | 22 (43.1) | 0.187 |
| SCCmec type II | 14/43 (32.6) | 3/21 (14.3) | 11/22 (50.0) | 0.012 |
| SCCmec type IV | 2/43 (4.7) | 1/21 (4.8) | 1/22 (4.5) | 0.976 |
| SCCmec type V | 22/43 (51.2) | 14/21 (66.7) | 8/22 (36.4) | 0.047 |
| SCCmec type Vt | 3/43 (7.0) | 2/21 (9.5) | 1/22 (4.5) | 0.522 |
| SCCmec type NT | 2/43 (4.7) | 1/21 (4.8) | 1/22 (4.5) | |
| Clindamycin-R | 33 (28.0) | 13 (19.4) | 20 (39.2) | 0.017 |
| Erythromycin-R | 40 (33.9) | 17 (25.4) | 23 (45.1) | 0.025 |
| TMP–SMX-R | 2 (1.7) | 1 (1.5) | 1 (2.0) | 0.841 |
|
| ||||
| I | 53 (44.9) | 27 (40.3) | 26 (51.0) | 0.246 |
| II | 65 (55.1) | 40 (59.7) | 25 (49.0) | 0.246 |
|
| ||||
| nonhemolytic | 12(10.2) | 6 (9.0) | 6 (11.8) | 0.617 |
|
| ||||
| A | 25 (21.2) | 17 (25.4) | 8 (15.7) | 0.201 |
| J | 14 (11.9) | 10 (14.9) | 4 (7.8) | 0.238 |
| M | 8 (6.8) | 5 (7.5) | 3 (5.9) | 0.728 |
| N | 12 (10.2) | 5 (7.5) | 7 (13.7) | 0.262 |
| P | 7 (5.9) | 4 (6.0) | 3 (5.9) | 0.984 |
NT = nontypeable; R = resistant; TMP–SMX = trimethoprim–sulfamethoxazole
1 The total number of SCCmec types was the number of isolates with oxacillin resistance.
Fig 2Dendrogram of pulsed field gel electrophoresis of 118 Staphylococcus lugdunensis isolates.
Summary of the pulsed-field gel electrophoresis results, antimicrobial resistance, and SCCmec and agr typing for Staphylococcus lugdunensis.
| PFGE type | Number (%) of isolates | Infection, n | Oxacillin resistant, n | Resistance profile | SCCmec- |
|---|---|---|---|---|---|
| A | 25 (21.2) | HAI, 17; Commensals, 8 | 21 | O, 19; O-C-E, 2 | SCCmec V- |
| J | 14 (11.9) | HAI, 10; Commensals, 4 | 1 | O-C-E, 1; C-E, 4 | SCCmec II-agr I, 1 |
| M | 8 (6.8) | HAI, 5; Commensals, 3 | 2 | O-C-E, 2; C-E,1 | SCCmec II- |
| N | 12 (10.2) | HAI, 4; CAI, 1; Commensals, 7 | 11 | O-C-E, 11 | SCCmec II- |
| P | 7 (5.9) | HAI, 3; CAI, 1; Commensals, 3 | 1 | O-E-SXT, 1; C-E, 2; E, 2; E-SXT, 1 | SCCmec IV-agr I, 1 |
| other | 52 (44.1) | HAI, 20; CAI, 6; Commensals, 26 | 7 | O, 5; O-C-E, 2; C-E, 8; E, 3 | SCCmec V- |
CAI = community-associated infection; HAI = healthcare-associated infection; NT = nontypeable; PFGE = pulsed-field gel electrophoresis
1C-E, clindamycin and erythromycin resistance; E, erythromycin resistance; E-SXT, erythromycin and trimethoprim–sulfamethoxazole resistance; O, oxacillin resistance; O-C-E, oxacillin, clindamycin, and erythromycin resistance; O-E-SXT, oxacillin, erythromycin, and trimethoprim–sulfamethoxazole resistance